

## DAFTAR PUSTAKA

- Abdullah, B., Balasubramanian, A., & Lazim, N. M. 2017. An Evidence-Based Approach to the Management of Nasopharyngeal Cancer. In *Вестник Росздравнадзора* (Vol. 4, Issue 1).
- Adham. 2012. Nasopharyngeal carcinoma in indonesia. *Chinese Journal of Cancer*, 31(4), 185–96.
- Adham, M., Kurniawan, A., Muhtadi, A., Roezin, A., Hermani, B., Gondhowiardjo, S., Tan, I., & Middeldorp, J. 2012. Nasopharyngeal Carcinoma in Indonesia: Epidemiology, Incidence, Signs, and Symptoms at Presentation. *Chin Journal Cancer*, 31(4), 185–189. <https://doi.org/10.5732/cjc.011.10328>
- Aldossary, S. A. 2022. Review on Pharmacology of Atropine, Clinical Use and Toxicity. *Biomedical and Pharmacology Journal*, 15(2), 691–697. <https://doi.org/10.13005/bpj/2408>
- Apte, R. S., Chen, D. S., Ferrara, N., Sciences, V., View, M., Diego, S., Diego, S., & Diego, S. 2020. VEGF in Signaling and Disease: Beyond Discovery and Development. *Cell*, 176(6), 1248–1264. <https://doi.org/10.1016/j.cell.2019.01.021>.VEGF
- Ariani, G., & Joewarini, E. 2015. Ekspresi E-cadherin dan Matrix Metalloproteinase -9 pada Invasi Miometrium Endometrioid Adenokarsinoma Endometrium. *Majalah Patologi*, 24(3), 17–23.
- Astina, K. Y., Ardani, N. M. A. E. K., & Daksa, N. P. 2023. Kadar Sel Leukosit Dan Eritrosit Selama Terapi Radiasi Pada Pasien Kanker Nasofaring Di Instalasi Radioterapi

Rsud Provinsi Nusa Tenggara Barat. *Jurnal Ilmu Kedokteran Dan Kesehatan*, 10(4), 1875–1884.

<https://doi.org/https://ejournalmalahayati.ac.id/index.php/kesehatan/article/view/9929>

Blanchard, P., Lee, A. W. M., Carmel, A., Wai Tong, N., Ma, J., Chan, A. T. C., Hong, R. L., Chen, M. Y., Chen, L., Li, W. F., Huang, P. Y., Kwong, D. L. W., Poh, S. S. X., Ngan, R., Mai, H. Q., Ollivier, C., Fountzilas, G., Zhang, L., Bourhis, J., ... Zhu, G. 2022. Meta-analysis of chemotherapy in nasopharynx carcinoma (MAC-NPC): An update on 26 trials and 7080 patients. *Clinical and Translational Radiation Oncology*, 32(November 2021), 59–68. <https://doi.org/10.1016/j.ctro.2021.11.007>

Bogdanov, A., Bogdanov, A., Chubenko, V., Volkov, N., Moiseenko, F., & Moiseyenko, V. 2022. Tumor acidity: From hallmark of cancer to target of treatment. *Frontiers in Oncology*, 12(August), 1–10. <https://doi.org/10.3389/fonc.2022.979154>

Botezatu. 2016. Mechanisms of Oncogene Activation World ' s largest Science , Technology & Medicine Open Access book publisher. *Open Science*, 1(March), 1–16. <https://doi.org/1249>

Cao, S. M., Simons, M. J., & Qian, C. N. 2011. The prevalence and prevention of nasopharyngeal carcinoma in China. *Chinese Journal of Cancer*, 30(2), 114–119. <https://doi.org/10.5732/cjc.010.10377>

Caravatta, L., Padula, G. D. A., Picardi, V., Macchia, G., Deodato, F., Massaccesi, M., Sofo, L., Pacelli, F., Rotondi, F., Cecere, G., Sallustio, G., Di Lullo, L., Piscopo, A., Mignogna, S., Bonomo, P., Cellini, N., Valentini, V., & Morganti, A. G. 2011. Concomitant boost radiotherapy and multidrug chemotherapy in the neoadjuvant

treatment of locally advanced rectal cancer: Results of a phase II study. *Acta Oncologica*, 50(8), 1151–1157. <https://doi.org/10.3109/0284186X.2011.582880>

Chan, J., Griffiths, K., Turner, A., Tobias, J., Clarmont, W., Delaney, G., Hutton, J., Olson, R., Penniment, M., Bourque, J.-M., Brundage, M., Rodin, D., Slotman, B., & Yap, M. L. 2023. Radiation Therapy and Indigenous Peoples in Canada and Australia: Building Paths Toward Reconciliation in Cancer Care Delivery. *International Journal of Radiation Oncology, Biology, Physics*, 116(2), 421–429. <https://doi.org/10.1016/j.ijrobp.2022.09.085>

Chen, A. M., Yang, C. C., Marsano, J., Liu, T., & Purdy, J. A. 2012. Intensity-modulated radiotherapy for nasopharyngeal carcinoma: Improvement of the therapeutic ratio with helical tomotherapy vs segmental multileaf collimator-based techniques. *British Journal of Radiology*, 85(1016), 537–543. <https://doi.org/10.1259/bjr/23807619>

Chen, C., Chen, T., Huang, C., Wang, J., & Fei, Z. 2017. Experience of weekly cisplatin concurrent with intensity-modulated radiotherapy for locally advanced nasopharyngeal carcinoma patients with resistance to neoadjuvant chemotherapy. *Medicine (United States)*, 96(44), 6–10. <https://doi.org/10.1097/MD.00000000000008434>

Chen, J., Chen, Q., Yao, J., Jiang, Y., Zhou, J., Zhao, H., & Cai, J. 2021. Changes in serum lactate dehydrogenase levels as markers of pathological response and prognosis in colorectal liver metastases patients receiving neoadjuvant chemotherapy followed by resection. *Annals of Palliative Medicine*, 10(10), 10276–10292. <https://doi.org/10.21037/apm-21-584>

- Chen, L., Gallicchio, L., Boyd-Lindsley, K., Tao, X. G., Robinson, K. A., Lam, T. K., Herman, J. G., Caulfield, L. E., Guallar, E., & Alberg, A. J. 2009. Alcohol consumption and the risk of nasopharyngeal carcinoma: a systematic review. *Nutrition and Cancer*, 61(1), 1–15. <https://doi.org/10.1080/01635580802372633>
- Chen, L., Li, Y. C., Hu, M., Zhao, S. J., & Yang, Q. W. 2022. Efficacy and safety of weekly versus triweekly cisplatin concurrent with radiotherapy in nasopharyngeal carcinoma A meta-analysis. *Medicine (United States)*, 101(52), E31842. <https://doi.org/10.1097/MD.00000000000031842>
- Chen, L., Lin, G., Chen, K., Wan, F., Liang, R., Sun, Y., Chen, X., & Zhu, X. 2020. VEGF knockdown enhances radiosensitivity of nasopharyngeal carcinoma by inhibiting autophagy through the activation of mTOR pathway. *Scientific Reports*, 10(1), 1–14. <https://doi.org/10.1038/s41598-020-73310-x>
- Chen, Z., Guo, Q., Lu, T., Lin, S., Zong, J., Zhan, S., Xu, L., & Pan, J. 2017. Pretreatment serum lactate dehydrogenase level as an independent prognostic factor of nasopharyngeal carcinoma in the intensity-modulated radiation therapy era. *Medical Science Monitor*, 23, 437–445. <https://doi.org/10.12659/MSM.899531>
- Chua, D., Wei, W. I., Sham, J. S. T., & Au, G. K. H. 2008. Capecitabine monotherapy for recurrent and metastatic nasopharyngeal cancer. *Japanese Journal of Clinical Oncology*, 38(4), 244–249. <https://doi.org/10.1093/jjco/hyn022>
- Cui, L., Chen, Z., Zeng, F., Jiang, X., Han, X., Yuan, X., Wu, S., Feng, H., Lin, D., Lu, W., Liu, X., Peng, X., & Yu, B. 2023. Impact of sex on treatment-related adverse effects and prognosis in nasopharyngeal carcinoma. *BMC Cancer*, 23(1), 1–11.

<https://doi.org/10.1186/s12885-023-11564-0>

Dasari, S., & Bernard Tchounwou, P. 2014. Cisplatin in cancer therapy: Molecular mechanisms of action. *European Journal of Pharmacology*, 740, 364–378.

<https://doi.org/10.1016/j.ejphar.2014.07.025>

de Bari, L., & Atlante, A. 2018. Including the mitochondrial metabolism of L-lactate in cancer metabolic reprogramming. *Cellular and Molecular Life Sciences : CMLS*,

75(15), 2763–2776. <https://doi.org/10.1007/s00018-018-2831-y>

Ding, J., Karp, J. E., & Emadi, A. 2017. Elevated lactate dehydrogenase (LDH) can be a marker of immune suppression in cancer: Interplay between hematologic and solid neoplastic clones and their microenvironments. *Cancer Biomarkers*, 19(4), 353–363.

<https://doi.org/10.3233/CBM-160336>

Dwijayanti, F., Prabawa, A., Besral, & Herawati, C. 2020. The Five-Year Survival Rate of Patients with Nasopharyngeal Carcinoma Based on Tumor Response after Receiving Neoadjuvant Chemotherapy, Followed by Chemoradiation, in Indonesia:

A Retrospective Study. *Oncology*, 98(3), 154–160.

<https://doi.org/10.1159/000504449>

Edirisinghe, S. T., Weerasekera, M., De Silva, D. K., Devmini, M. T., Pathmaperuma, S.,

Wijesinghe, G. K., Nisansala, T., Maddumage, A., Huzaini, H., Rich, A. M., De Silva,

H., Trudy, M., Goonesinghe, R., De Silva, K., & Yasawardene, S. 2023. Vascular

Endothelial Growth Factor A (VEGF-A) and Vascular Endothelial Growth Factor

Receptor 2 (VEGFR-2) as Potential Biomarkers for Oral Squamous Cell Carcinoma:

A Sri Lankan Study. *Asian Pacific Journal of Cancer Prevention*, 24(1), 267–274.

<https://doi.org/10.31557/APJCP.2023.24.1.267>

Eguchi, R., Kawabe, J. I., & Wakabayashi, I. 2022. VEGF-Independent Angiogenic Factors: Beyond VEGF/VEGFR2 Signaling. *Journal of Vascular Research*, 59(2), 78–89. <https://doi.org/10.1159/000521584>

Farhana, A., & Lappin, S. 2020. *Biochemistry, Lactate Dehydrogenase*. Treasure Island (FL): StatPearls Publishing.

Feng, Y., Xiong, Y., Qiao, T., Li, X., Jia, L., & Han, Y. 2018. Lactate dehydrogenase A: A key player in carcinogenesis and potential target in cancer therapy. *Cancer Medicine*, 7(12), 6124–6136. <https://doi.org/10.1002/cam4.1820>

Ferrara, N., & Adamis, A. P. 2016. Ten years of anti-vascular endothelial growth factor therapy. *Nature Reviews. Drug Discovery*, 15(6), 385–403. <https://doi.org/10.1038/nrd.2015.17>

Fiorisa, E. S., Rhomdhoni, A. C., Sutikno, B., & Sensusiati, A. D. 2020. Decrease of epstein-barr virus anti early antigen imunoglobulin a levels and primary tumor size in post-cisplatin-paclitaxel chemotherapy in nasopharyngeal carcinoma patients. *Indian Journal of Forensic Medicine and Toxicology*, 14(2), 1541–1545. <https://doi.org/10.37506/ijfmt.v14i2.3144>

Fitrianisa, N., Sulistyanto, A., & Ayuningtyas, P. R. 2023. Differences in Quality of Life of Nasopharyngeal Carcinoma Patients at Rsi Sultan Agung Semarang Observational Analytical Studies in Age, Gender, and Stages of Cancer. *International Journal of Human and Health Sciences*, 07(04), 321–326. <https://doi.org/http://dx.doi.org/10.31344/ijhhs.v7i4.593>

- Forkasiewicz, A., Dorociak, M., Stach, K., Szelachowski, P., Tabola, R., & Augoff, K. 2020. The usefulness of lactate dehydrogenase measurements in current oncological practice. *Cellular and Molecular Biology Letters*, 25(1). <https://doi.org/10.1186/s11658-020-00228-7>
- Ghoshal, S., Goda, J. S., Mallick, I., Kehwar, T. S., & Sharma, S. C. 2008. Concomitant Boost Radiotherapy Compared with Conventional Radiotherapy in Squamous Cell Carcinoma of the Head and Neck - a Phase III Trial from a Single Institution in India. *Clinical Oncology*, 20(3), 212–220. <https://doi.org/10.1016/j.clon.2008.01.011>
- Ginting, H. I. S., & Harahap, M. S. 2024. Nasopharyngeal Carcinoma in the Nias Tribe Indonesia: Prevalence, Risk Factors, and Characteristics. *Archives of The Medicine and Case Reports*, 6(1), 1184–1196. <https://doi.org/10.37275/amcr.v6i1.674>
- Girgis, H., Masui, O., White, N. M. A., Scorilas, A., Rotondo, F., Seivwright, A., Gabril, M., Filter, E. R., Girgis, A. H. A., Bjarnason, G. A., Jewett, M. A. S., Evans, A., Al-Haddad, S., Siu, K. W. M., & Yousef, G. M. 2014. Lactate Dehydrogenase A is a potential prognostic marker in clear cell renal cell carcinoma. *Molecular Cancer*, 13(1), 1–10. <https://doi.org/10.1186/1476-4598-13-101>
- Guo, R., Mao, Y., Tang, L., Chen, L., Sun, Y., & Ma, J. 2019. Nasopharyngeal carcinoma special feature: review article the evolution of nasopharyngeal carcinoma staging. *British Journal of Radiology*, 92(1102), 20190244.
- Hakim, A., Wahyudin, E., & Pieter, N. A. L. 2023. Effects of Combination of Cisplatin and Paclitaxel Chemotherapy on Tumor Mass in Nasopharyngeal Carcinoma Patients at Dr. Wahidin Sudirohusodo Hospital Makassar with the RECIST Method. *Jurnal*

*Farmasi Galenika (Galenika Journal of Pharmacy) (e-Journal)*, 9(2), 189–196.  
<https://doi.org/10.22487/j24428744.2023.v9.i2.16236>

Hamid, G. A. 2021. Epidemiology and Outcomes of Nasopharyngeal Carcinoma. In *Pharynx - Diagnosis and Treatment* (pp. 1–15). IntechOpen.  
<https://doi.org/10.5772/INTECHOPEN.96802>

Hua, Y. J., Ou-Yang, Y. F., Zou, X., Xia, L., Luo, D. H., & Chen, M. Y. 2021. The Effect of Prolonged Duration of Intensity Modulated Radiotherapy for Nasopharyngeal Carcinoma. *Frontiers in Oncology*, 11(September).  
<https://doi.org/10.3389/fonc.2021.648637>

Iramanda, D. S. 2021. Quality Assurance (Qa) Dan Quality Control (Qc) Cobalt. *Jurnal Biosains Pascasarjana*, 23(2), 61. <https://doi.org/10.20473/jbp.v23i2.2021.61-74>

Irawan, C., Nufus, H., Rachmadi, L., Harimurti, K., Munandar, A., & Yunus, R. 2022a. The relationship of vascular endothelial growth factor and osteopontin expression with 3-year progression-free survival of locally advanced nasopharyngeal cancer patients treated with platinumbased chemoradiation. *Współczesna Onkologia*, 26(3), 220–228. <https://doi.org/10.5114/wo.2022.120698>

Irawan, C., Nufus, H., Rachmadi, L., Harimurti, K., Munandar, A., & Yunus, R. E. 2022b. The relationship of vascular endothelial growth factor and osteopontin expression with 3-year progression-free survival of locally advanced nasopharyngeal cancer patients treated with platinum-based chemoradiation. *Wspolczesna Onkologia*, 26(3), 220–228. <https://doi.org/10.5114/wo.2022.120698>

Itatani, Y., & Kawada, K. 2018. Resistance to Anti-Angiogenic Therapy in Cancer —

Alterations to Anti-VEGF Pathway. *International Journal of Molecular Sciences*, 19(1232), 1–18. <https://doi.org/10.3390/ijms19041232>

Jayson, G. C., Kerbel, R., Ellis, L. M., & Harris, A. L. 2016. Antiangiogenic therapy in oncology: current status and future directions. *Lancet (London, England)*, 388(10043), 518–529. [https://doi.org/10.1016/S0140-6736\(15\)01088-0](https://doi.org/10.1016/S0140-6736(15)01088-0)

Jiromaru, R., Nakagawa, T., & Yasumatsu, R. 2022. Advanced Nasopharyngeal Carcinoma: Current and Emerging Treatment Options. *Cancer Management and Research*, 14(September), 2681–2689. <https://doi.org/10.2147/CMAR.S341472>

Kaitouni, Z. I., Ammor, Y. M., Benyouness, L., Darfaoui, M., Lalya, I., Elomrani, A., & Khouchani, M. 2023. Therapeutic Aspects of Undifferentiated Nasopharyngeal Cancer in Young Adults (Under 40 Years Old). *SAS Journal of Medicine*, 9(06), 650–654. <https://doi.org/10.36347/sasjm.2023.v09i06.018>

Kandaz, M., Balsak, A., Aydogdu, K., & Cobanoglu, H. B. 2023. Acute Side Effects of Combined Chemotherapy with Intensity-Modulated Radiotherapy in The Treatment of Nasopharyngeal Carcinoma. *Farabi Tip Dergisi*, 2(4), 1–6. <https://doi.org/10.59518/farabimedj.1323840>

Khan, A. A., Allemailem, K. S., Alhumaydhi, F. A., Gowder, S. J. T., & Rahmani, A. H. 2020. The Biochemical and Clinical Perspectives of Lactate Dehydrogenase: An Enzyme of Active Metabolism. *Endocrine, Metabolic & Immune Disorders Drug Targets*, 20(6), 855–868. <https://doi.org/10.2174/1871530320666191230141110>

Kim, T. H., Ko, Y. H., Lee, M. A., Kim, B., Chung, S. R., Yoo, I. R., Jung, C.-K., Kim, Y.-S., Kim, M. S., Sun, D.-I., Hong, Y. S., Lee, K. S., & Kang, J.-H. 2008. Treatment

Outcome of Cisplatin-based Concurrent Chemoradiotherapy in the Patients with Locally Advanced Nasopharyngeal Cancer. *Cancer Research and Treatment*, 40(2), 62. <https://doi.org/10.4143/crt.2008.40.2.62>

Kiyota, N., Tahara, M., Mizusawa, J., Kodaira, T., Fujii, H., Yamazaki, T., Mitani, H., Iwae, S., Fujimoto, Y., Onozawa, Y., Hanai, N., Ogawa, T., Hara, H., Monden, N., Shimura, E., Minami, S., Fujii, T., Tanaka, K., Homma, A., ... Hayashi, R. 2022. Weekly Cisplatin Plus Radiation for Postoperative Head and Neck Cancer (JCOG1008): A Multicenter, Noninferiority, Phase II/III Randomized Controlled Trial. *Journal of Clinical Oncology*, 40(18), 1980–1990. <https://doi.org/10.1200/JCO.21.01293>

Kong, M., Lim, Y. J., & Kim, Y. 2018. Concurrent chemoradiotherapy for loco-regionally advanced nasopharyngeal carcinoma: Treatment outcomes and prognostic factors. *Asian Pacific Journal of Cancer Prevention*, 19(6), 1591–1599. <https://doi.org/10.22034/APJCP.2018.19.6.1591>

Kumar, V., Abbas, A. K., & Aster, J. C. 2021. *Robbins & Cotran Pathologic Basis of Disease* (10th ed.). Elseiver.

Kurnianto, P., Maslebu, G., Muninggar, J., & Hidayatullah, M. 2023. Quality Assurance Plan on a Linear Accelerator (LINAC) Plane on Nasopharynx Cancer (NFC) by using Prowess Panther 5.10 at Radiotherapy Installation Ken Saras Hospital. *Advance Sustainable Science Engineering and Technology*, 5(2), 0230202. <https://doi.org/10.26877/asset.v5i2.15247>

Lasrado, S., Moras, K., Pinto, G. J. O., Bhat, M., Hegde, S., Sathian, B., & Luis, N. A. 2014. Role of concomitant chemoradiation in locally advanced head and neck

cancers. *Asian Pacific Journal of Cancer Prevention : APJCP*, 15(10), 4147–4152.  
<https://doi.org/10.7314/apjcp.2014.15.10.4147>

Lau. 2013. Secular trends of salted fish consumption and nasopharyngeal carcinoma: a multi-jurisdiction ecological study in 8 regions from 3 continent. *BMC Cancer*, 13(1), 298.

Lau, B., Vo, J., Shing, J., Pollom, E., & Taparra, K. 2023. A Large National Study on Racial Disparities among Asian American, Native Hawaiian, and Other Pacific Islander Cancer Patients Who Refuse Radiation Therapy and Surgery. *International Journal of Radiation Oncology*, 117(2), e33.  
<https://doi.org/10.1016/j.ijrobp.2023.06.720>

Le, X., & Hanna, E. Y. 2018. Optimal regimen of cisplatin in squamous cell carcinoma of head and neck yet to be determined. *Annals of Translational Medicine*, 6(11), 229–229. <https://doi.org/10.21037/atm.2018.05.10>

Lee, A., Kitpanit, S., Chilov, M., Langendijk, J. A., Lu, J., & Lee, N. Y. 2021. A systematic review of proton therapy for the management of nasopharyngeal cancer. *International Journal of Particle Therapy*, 8(1), 119–130.  
<https://doi.org/10.14338/IJPT-20-00082.1>

Li, G., Gao, J., Tao, Y.-L., Xu, B.-Q., Tu, Z.-W., Liu, Z.-G., Zeng, M.-S., & Xia, Y.-F. 2012. Increased pretreatment levels of serum LDH and ALP as poor prognostic factors for nasopharyngeal carcinoma. *Chinese Journal of Cancer*, 31(4), 197–206.  
<https://doi.org/10.5732/cjc.011.10283>

Li, J., Wu, M., Lu, H., Chen, Q., Lin, Z., & Wang, L. 2016. Pretreatment serum lactate

dehydrogenase is an independent prognostic factor for patients receiving neoadjuvant chemotherapy for locally advanced cervical cancer. *Cancer Med*, 5(8), 1863–1872. <https://doi.org/10.1002/cam4.779>

Li, W.-Z., Lv, X., Hu, D., Lv, S.-H., Liu, G.-Y., Liang, H., Ye, Y.-F., Yang, W., Zhang, H.-X., Yuan, T.-Z., Wang, D.-S., Lu, N., Ke, L.-R., Tang, W.-B., Tong, L.-H., Chen, Z.-J., Liu, T., Cao, K.-J., Mo, H.-Y., ... Xia, W.-X. 2022. Effect of Induction Chemotherapy With Paclitaxel, Cisplatin, and Capecitabine vs Cisplatin and Fluorouracil on Failure-Free Survival for Patients With Stage IVA to IVB Nasopharyngeal Carcinoma: A Multicenter Phase 3 Randomized Clinical Trial. *JAMA Oncology*, 8(5), 706–714. <https://doi.org/10.1001/jamaoncol.2022.0122>

Li, Y. H., Hu, C. F., Shao, Q., Huang, M. Y., Hou, J. H., Xie, D., Zeng, Y. X., & Shao, J. Y. 2008. Elevated expressions of survivin and VEGF protein are strong independent predictors of survival in advanced nasopharyngeal carcinoma. *Journal of Translational Medicine*, 6, 1–11. <https://doi.org/10.1186/1479-5876-6-1>

Li, Y., Wang, J., Ma, X., Li, T., Yan, Y., Xue, C., Hui, B., Liu, R., Ma, H., & Ren, J. 2016. A review of neoadjuvant chemoradiotherapy for locally advanced rectal cancer. *International Journal of Biological Sciences*, 12(8), 1022–1031. <https://doi.org/10.7150/ijbs.15438>

Li, Z., Li, C., Yang, D., Song, J., Liu, T., Zhou, Z., Zhou, L., & Kang, M. 2022. Comparing the efficacy and safety of cisplatin and other platinum-based chemotherapies in locally advanced nasopharyngeal carcinoma: a systematic review and meta-analysis. *BMC Cancer*, 22(1), 1–15. <https://doi.org/10.1186/s12885-022-09712-z>

- Liemiyah, R., Ruspita, D. A., Naftali, Z., Muyassaroh, M., & Farokah, F. 2024. Epidemiological Characteristics and 3-year Overall Survival Outcome of Nasopharyngeal Cancer in Central Java: A Single Institution Retrospective Study. *Indonesian Journal of Cancer*, 18(2), 143–155. <https://doi.org/10.33371/ijoc.v18i2.1083>
- Lin. 2015. Smoking and nasopharyngeal carcinoma mortality: a cohort study of 101,823 adults in 53 Guangzhou, Cina. *BMC Cancer*, 15(1), 906.
- Lin, Y., Yu, X., Lu, L., Chen, H., Wu, J., Chen, Y., Lin, Q., Wang, X., Chen, X., & Chen, X. 2023. Age is a significant biomarker for the selection of neoadjuvant chemotherapy plus radiotherapy versus concurrent chemoradiotherapy in patients with advanced nasopharyngeal carcinoma. *Cancer Biomarkers*, 37(1), 1–11. <https://doi.org/10.3233/CBM-210357>
- Long, G., Tang, W., Fu, X., Liu, D., Zhang, L., Hu, G., Hu, G., & Sun, W. 2019. Pre-treatment serum lactate dehydrogenase predicts distant metastasis and poor survival in nasopharyngeal carcinoma. *Journal of Cancer*, 10(16), 3657–3664. <https://doi.org/10.7150/jca.32716>
- Long, M., Fu, Z., Li, P., & Nie, Z. 2017. Cigarette smoking and the risk of nasopharyngeal carcinoma: a meta-analysis of epidemiological studies. *BMJ Open*, 7(10), e016582. <https://doi.org/10.1136/bmjopen-2017-016582>
- M'hamdi, H., Baizig, N. M., ELHadj, O. E. A., M'hamdi, N., Attia, Z., Gritli, S., Gamoudi, A., EL May, M. V., & A El May. 2016. Usefulness of IGF-1 serum levels as diagnostic marker of nasopharyngeal carcinoma. *Immunobiology*, 221(11), 1304–1308.

<https://doi.org/10.1016/j.imbio.2016.05.008>

Maas, B., Ho, C., Hamilton, S., Leedy, D., & Berthelet, E. 2018. Impact of Neoadjuvant Chemotherapy on the Administration of Concurrent Chemoradiation for Locally Advanced Nasopharyngeal Carcinoma. *Cureus*, 10(7).  
<https://doi.org/10.7759/cureus.2971>

Makni, L., Stayoussef, M., Ghazouani, E., Mezlini, A., Almawi, W. Y., & BesmaYacoubi-Loueslati. 2016. Distinct association of VEGF-A polymorphisms with laryngeal and nasopharyngeal cancer. *Meta Gene*, 10, 90–94.  
<https://doi.org/10.1016/j.mgene.2016.02.003>

Mansoor, M., Shakil, F., Jalal, U., Shahid, F., Jamal, M., Ali, A. S., Abbasi, F. A., Hijazi, H., Imran, H., Hirani, S., Javaid, A., Abu Bakar, A., Shah, A. A., Varrassi, G., Khatri, M., & Kumar, S. 2023. Comparison of the Efficacy of Cisplatin/Paclitaxel Versus Carboplatin/Paclitaxel in Improving Survival and Quality of Life in the Advanced Ovarian Cancer Patient Population: A Systematic Review and Meta-Analysis of Randomized Control Trials. *Cureus*, 15(12), 1–18.  
<https://doi.org/10.7759/cureus.51011>

Melincovici, C. S., Boşca, A. B., Şuşman, S., Mărginean, M., Mişu, C., Istrate, M., Moldovan, I. M., Roman, A. L., & Mişu, C. M. 2018. Vascular endothelial growth factor (VEGF) – key factor in normal and pathological angiogenesis. *Romanian Journal of Morphology and Embryology*, 59(2), 455–467.

Minalita, E., Yuniar Sari, N., Kata Kunci, A., Nasofaring, K., Diri, K., & Kanker Nasofaring, P. 2024. Gambaran Konsep Diri pada Pasien Kanker Nasofaring-ShareAlike 4.0

International (CC BY-SA 4.0). *Indonesian Research Journal on Education Web Jurnal Indonesian Research Journal on Education*, 4(2020), 3522–3528.

Mol. 2013. Oncogenes as Therapeutic Targets in Cancer : A Review. *Journal of Dental and Medical Sciences*, 5(2), 46–56.

Nafisa, I. M., Utama, M. S., Sunardi, M. A., & Adibrata, A. A. 2022. Profile of Nasopharyngeal Cancer Patients who Underwent Radiotherapy in Dr. Hasan Sadikin General Hospital Bandung. *Indonesian Journal of Cancer*, 16(2), 88. <https://doi.org/10.33371/ijoc.v16i2.869>

Nazeer, F., Poulouse, J. V., & Kainickal, C. T. 2022. Induction chemotherapy in nasopharyngeal carcinoma- A systematic review of phase III clinical trials. *Cancer Treatment and Research Communications*, 32(June), 100589. <https://doi.org/10.1016/j.ctarc.2022.100589>

Oh, G. S., Kim, H. J., Shen, A. H., Lee, S. Bin, Khadka, D., Pandit, A., & So, H. S. 2014. Cisplatin-induced kidney dysfunction and perspectives on improving treatment strategies. *Electrolyte and Blood Pressure*, 12(2), 55–65. <https://doi.org/10.5049/EBP.2014.12.2.55>

Okada, T., Okamoto, I., Sato, H., Ito, T., Miyake, K., & Tsukahara, K. 2021. Efficacy and safety of paclitaxel combined with cetuximab for head and neck squamous cell carcinoma. *In Vivo*, 35(2), 1253–1259. <https://doi.org/10.21873/INVIVO.12376>

Paiaf, F., Di Cataldo, V., Zei, G., Pasquetti, E. M., Cecchini, S., Meattini, I., Mangoni, M., Agresti, B., Iermano, C., Bonomo, P., & Biti, G. 2012. Role of chemotherapy in nasopharyngeal carcinoma. *Oncology Reviews*, 6(1), 1–6.

<https://doi.org/10.4081/oncol.2012.e1>

Pala, M., Novakova, P., Drbohlavova, T., Vrana, A., Pechacova, Z., Votavova, K., Subrt, A., Krejci, D., Holeckova, P., & Tesarova, P. 2023. Negative Prognostic Impact of Smoking on Long-term Survival in Patients With Nasopharyngeal Carcinoma Treated With Curative (Chemo)radiotherapy. *In Vivo*, 37(4), 1775–1785. <https://doi.org/10.21873/invivo.13266>

Passarella, S., & Schurr, A. 2018. L-Lactate Transport and Metabolism in Mitochondria of Hep G2 Cells-The Cori Cycle Revisited. *Frontiers in Oncology*, 8, 120. <https://doi.org/10.3389/fonc.2018.00120>

PERHATI-KL. 2017. Karsinoma Nasofaring. In *Penerbit Buku Kedokteran*.

Posner, M. R., Hershock, D. M., Blajman, C. R., Mickiewicz, E., Winquist, E., Gorbounova, V., Tjulandin, S., Shin, D. M., Cullen, K., Ervin, T. J., Murphy, B. A., Racz, L. E., Cohen, R. B., Spaulding, M., Tishler, R. B., Roth, B., Viroglio, R. del C., Venkatesan, V., Romanov, I., ... Haddad, R. I. 2007. Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer. *New England Journal of Medicine*, 357(17), 1705–1715. <https://doi.org/10.1056/nejmoa070956>

Pu, L., Su, L., & Kang, X. 2019. The efficacy of cisplatin on nasopharyngeal carcinoma cells may be increased via the downregulation of fibroblast growth factor receptor 2. *International Journal of Molecular Medicine*, 44(1), 57–66. <https://doi.org/10.3892/ijmm.2019.4193>

Rahman. 2015. Tinjauan pustaka faktor risiko non viral pada karsinoma nasofaring. *Jurnal Kesehatan Andalas*, 4(3), 988–95.

Ren. 2017. Effect of family history of cancers and environmental factors on risk of nasopharyngeal carcinoma in Guangdong. *Cancer Epidemiology Biomarkers and Prevention*, 34(4), 2017.

Römer, T., Franzen, S., Kravets, H., Farrag, A., Makowska, A., Christiansen, H., Eble, M. J., Timmermann, B., Staatz, G., Mottaghy, F. M., Bührlen, M., Hagenah, U., Puzik, A., Hern, P., Greiner, J., & Jorch, N. 2022. *Multimodal Treatment of Nasopharyngeal Carcinoma in Interim Cohort*.

Rothschild, S. I., Helfenstein, S., Riesterer, O., Meier, U. R., Papachristofilou, A., Kasenda, B., & Pless, M. 2017. 3-weekly or weekly cisplatin concurrently with radiotherapy for patients with locally advanced squamous cell carcinoma of the head and neck: A multicentre, retrospective analysis. *Annals of Oncology*, 28, v382. <https://doi.org/10.1093/annonc/mdx374.021>

Sadremomtaz, A., Mansouri, K., Alemzadeh, G., Safa, M., Rastaghi, A. E., & Asghari, S. M. 2018. Dual blockade of VEGFR1 and VEGFR2 by a novel peptide abrogates VEGF-driven angiogenesis, tumor growth, and metastasis through PI3K/AKT and MAPK/ERK1/2 pathway. *Biochimica et Biophysica Acta (BBA) - General Subjects*, 1862(12), 2688–2700. <https://doi.org/https://doi.org/10.1016/j.bbagen.2018.08.013>

Santana-Davila, R., Szabo, A., Arce-Lara, C., Williams, C. D., Kelley, M. J., & Whittle, J. 2014. Cisplatin versus carboplatin-based regimens for the treatment of patients with metastatic lung cancer. An analysis of Veterans Health Administration data. *Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer*, 9(5), 702–709.

<https://doi.org/10.1097/JTO.0000000000000146>

Setakornnukul, J., & Thephamongkhol, K. 2018. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma. *BMC Cancer*, 18(1), 2–9. <https://doi.org/10.1186/s12885-018-4210-3>

Sharma, D., Singh, M., & Rani, R. 2022. Role of LDH in tumor glycolysis: Regulation of LDHA by small molecules for cancer therapeutics. *Seminars in Cancer Biology*, 87, 184–195. <https://doi.org/10.1016/j.semcancer.2022.11.007>

Siemert, J., Wald, T., Kolb, M., Pettinella, I., Böhm, U., Pirlich, M., Wiegand, S., Dietz, A., & Wichmann, G. 2021. Pre-therapeutic vegf level in plasma is a prognostic biomarker in head and neck squamous cell carcinoma (Hnscc). *Cancers*, 13(15). <https://doi.org/10.3390/cancers13153781>

Simo, R., Robinson, M., Lei, M., Sibtain, A., & Hickey, S. 2016. Nasopharyngeal carcinoma: United Kingdom National Multidisciplinary Guidelines. *The Journal of Laryngology and Otology*, 130(S2), S97–S103. <https://doi.org/10.1017/s0022215116000517>

Srivastava, V. K., Gara, R. K., Rastogi, N., Prasad, D., Ahmed, M. K., Gupta, S., Goel, M. M., & Lal, M. 2014. Serum Vascular Endothelial Growth Factor-A ( VEGF-A ) as a Biomarker in Squamous Cell Carcinoma of Head and Neck Patients Undergoing Chemoradiotherapy. *Asian Pacific Journal of Cancer Prevention*, 15.

Sun, X., Tong, L., Wang, Y., Wu, Y., Sheng, H., & Lu, L. 2011. Can global variation of nasopharynx cancer be retrieved from the combined analyses of IARC Cancer

Information (CIN) databases? *PLoS ONE*, 6(7), 1–9.  
<https://doi.org/10.1371/journal.pone.0022039>

Susanto, S. A., Dewi, Y. A., & Saputri, R. A. H. 2022. Assessment of Response to Chemoradiation and Radiation Therapy in Patients with Nasopharyngeal Carcinoma. *Open Access Macedonian Journal of Medical Sciences*, 10(B), 2307–2312.  
<https://doi.org/10.3889/oamjms.2022.10438>

Szturz, P., Wouters, K., Kiyota, N., Tahara, M., Prabhash, K., Noronha, V., Adelstein, D., Van Gestel, D., & Vermorcken, J. B. 2019. Low-dose vs. high-dose cisplatin: Lessons learned from 59 chemoradiotherapy trials in head and neck cancer. *Frontiers in Oncology*, 9(FEB). <https://doi.org/10.3389/fonc.2019.00086>

Takeshita, N., Enokida, T., Okano, S., Fujisawa, T., Wada, A., Sato, M., Tanaka, H., Tanaka, N., Motegi, A., Zenda, S., Akimoto, T., & Tahara, M. 2022. Induction chemotherapy with paclitaxel, carboplatin and cetuximab for locoregionally advanced nasopharyngeal carcinoma: A single-center, retrospective study. *Frontiers in Oncology*, 12(August), 1–10. <https://doi.org/10.3389/fonc.2022.951387>

Taparra, K., Qu, V., Lau, B., & Pollom, E. 2023. A National Cancer Disparities Analysis of Predictors for Radiation Therapy Refusal by Race. *International Journal of Radiation Oncology, Biology, Physics*, 116(1), 96–102.  
<https://doi.org/10.1016/j.ijrobp.2023.01.033>

Tchounwou, P. B., Dasari, S., Noubissi, F. K., Ray, P., & Kumar, S. 2021. Advances in our understanding of the molecular mechanisms of action of cisplatin in cancer therapy. *Journal of Experimental Pharmacology*, 13, 303–328.

<https://doi.org/10.2147/JEP.S267383>

Van Wilpe, S., Koornstra, R., Den Brok, M., De Groot, J. W., Blank, C., De Vries, J., Gerritsen, W., & Mehra, N. 2020. Lactate dehydrogenase: a marker of diminished antitumor immunity. *Oncolmmunology*, 9(1), 1–11. <https://doi.org/10.1080/2162402X.2020.1731942>

Velma, V., Dasari, S. R., & Tchounwou, P. B. 2016. Low doses of cisplatin induce gene alterations, cell cycle arrest, and apoptosis in human promyelocytic leukemia cells. *Biomarker Insights*, 11, 113–121. <https://doi.org/10.4137/Bmi.s39445>

Wan, X., Wei, L., Li, H., Dong, M., Lin, Q., Ma, X., Huang, P., Wen, J., Li, X., Chen, J., Ruan, D., Lin, Z., Chen, Z., Liu, Q., Wu, X., & Hong, M. 2013. High pretreatment serum lactate dehydrogenase level correlates with disease relapse and predicts an inferior outcome in locally advanced nasopharyngeal carcinoma. *European Journal of Cancer (Oxford, England: 1990)*, 49(10), 2356–2364. <https://doi.org/10.1016/j.ejca.2013.03.008>

Wang, F., Peng, L., Wang, Y., & Liu, X. 2018. A meta-analysis of vascular endothelial growth factor for nasopharyngeal cancer prognosis. *Frontiers in Oncology*, 8(OCT), 1–9. <https://doi.org/10.3389/fonc.2018.00486>

Wang, Q., Xie, H., Li, Y., Theodoropoulos, N., Zhang, Y., Jiang, C., Wen, C., Rozek, L. S., & Boffetta, P. 2022. Racial and ethnic disparities in nasopharyngeal cancer with an emphasis among Asian Americans. *International Journal of Cancer*, 151(8), 1291–1303. <https://doi.org/10.1002/ijc.34154>

Wang, R.-X., Chen, S., Huang, L., Zhou, Y., & Shao, Z.-M. 2019. Monitoring Serum VEGF

in Neoadjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer : A New Strategy for Early Prediction of Treatment Response and Patient Survival. *The Oncologist*, 24, 753–761. <https://doi.org/10.1634/theoncologist.2017-0602>

Wang, W., Peng, S., Wu, H., Luo, Y., Yuan, F., Lin, Z., Cheng, G., & Chen, S. 2021. Association of tumor downstaging after neoadjuvant chemotherapy with survival in patients with locally advanced nasopharyngeal carcinoma: a retrospective cohort study. *Journal of Cancer Research and Clinical Oncology*, 147(10), 2913–2922. <https://doi.org/10.1007/s00432-021-03690-8>

Wang, X., Bove, A. M., Simone, G., & Ma, B. 2020. Molecular Bases of VEGFR-2-Mediated Physiological Function and Pathological Role. *Frontiers in Cell and Developmental Biology*, 8(November), 1–12. <https://doi.org/10.3389/fcell.2020.599281>

Wei, Z., Zeng, X., Xu, J., Duan, X., & Xie, Y. 2014. Prognostic value of pretreatment serum levels of lactate dehydrogenase in nonmetastatic nasopharyngeal carcinoma: single-site analysis of 601 patients in a highly endemic area. *OncoTargets and Therapy*, 7, 739–749. <https://doi.org/10.2147/OTT.S59804>

William, I. W. 2012. Nasopharyngeal Cancer. *Bailey Head and Surgery Otolaryngology*. 4, 4, 213–224.

Winata, I. G. S., & Christyani, F. 2024. High Expression of Vascular Endothelial Growth Factor , Ki-67 , and Protein 53 are Risk Factors for Poor Response of Paclitaxel-Carboplatin Neoadjuvant Chemotherapy in Stadium IB3 , IIA2 , and IIB Cervical Cancer. *Asian Pacific Journal of Cancer Prevention*, 25, 2625–2631.

<https://doi.org/10.31557/APJCP.2024.25.8.2625>

- Wu, L., Li, C., & Pan, L. 2018. Nasopharyngeal carcinoma: A review of current updates. *Experimental and Therapeutic Medicine*, 15(4), 3687–3692. <https://doi.org/10.3892/etm.2018.5878>
- Wyss. 2013. Cigarette, cigar, and pipe smoking and the risk of head and neck cancers: Pooled analysis in the international head and neck cancer epidemiology consortium. *American Journal of Epidemiology*, 178(5), 679–90.
- Xiang, Z. F., Hu, D. F., Xiong, H. C., Li, M. Y., Zhang, Z. C., Shen, E. D., Li, W. Z., & Xiang, Y. Q. 2021. Benefit of chemotherapy in stage III nasopharyngeal carcinoma: Analysis of the surveillance, epidemiology, and end results database. *Oral Oncology*, 117, 105284. <https://doi.org/10.1016/j.oraloncology.2021.105284>
- Xing, W., Li, X., Zhou, Y., Li, M., & Zhu, M. 2023. Lactate metabolic pathway regulates tumor cell metastasis and its use as a new therapeutic target. *Exploration of Medicine*, 4, 541–559. <https://doi.org/10.37349/emed.2023.00160>
- Xu, X. 2024. Mechanism of LDH and IL-8 Involved in pancreatic cancer Pain and the Correlation of Pain Degree. *Journal of Medical Biochemistry*, 1–7. <https://doi.org/10.5937/jomb0-48160>
- Yan, H., Wang, R., Yu, J., & Jiang, S. 2010. Predictive value of Smac , VEGF and Ki-67 in rectal cancer treated with neoadjuvant therapy. *Oncology Letters*, 641–647. <https://doi.org/10.3892/ol>
- Yang, Y., & Cao, Y. 2022. The impact of VEGF on cancer metastasis and systemic

disease. *Seminars in Cancer Biology*, 86(P3), 251–261.  
<https://doi.org/10.1016/j.semcancer.2022.03.011>

Yang, Z., Zuo, Q., Liu, R., Wu, H., Xiong, L., Jia, J., & Xiang, Z. 2023. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy with or without nimotuzumab in the treatment of locally advanced nasopharyngeal carcinoma: a retrospective study. *BMC Cancer*, 23(1), 1–9. <https://doi.org/10.1186/s12885-023-11608-5>

Yenita. 2012. Penelitian Korelasi antara Latent Membrane Protein-1 Virus Epstein-Barr dengan P53 pada Karsinoma Nasofaring. *Jurnal Kesehatan Andalas*, 1(1), 4–6.

Yi, X. Y. L., Cao, D. H., You, P. H., Xiong, X. Y., Zheng, X. N., Peng, G., Liao, D. Z., Li, H., Yang, L., & Ai, J. Z. 2022. Neoadjuvant chemotherapy for patients with locally advanced penile cancer: An updated evidence. *Asian Journal of Andrology*, 24(2), 180–185. <https://doi.org/10.4103/aja202188>

Yong. 2017. Associations of lifestyle and diet with the risk of nasopharyngeal carcinoma in Singapore: a case-control study. *Chinese Journal of Cancer*, 36(1), 3.

Yuan, J. M., Wang, X. L., Xiang, Y. B., Gao, Y. T., Ross, R. K., & Yu, M. C. 2000. Preserved foods in relation to risk of nasopharyngeal carcinoma in Shanghai, China. *International Journal of Cancer*, 85(3), 358–363. [https://doi.org/10.1002/\(sici\)1097-0215\(20000201\)85:3<358::aid-ijc11>3.0.co;2-e](https://doi.org/10.1002/(sici)1097-0215(20000201)85:3<358::aid-ijc11>3.0.co;2-e)

Zhang, M., Wei, S., Su, L., Wenlong, L., & Hong, J. 2016. Prognostic significance of pretreated serum lactate dehydrogenase level in nasopharyngeal carcinoma among Chinese population A meta-analysis. *Medicine (United States)*, 95(35).

<https://doi.org/10.1097/MD.0000000000004494>

Zhang, W. M., Mo, Q. Y., & Zhu, X. D. 2023. Contribution of age at diagnosis to cancer-specific survival of nasopharyngeal carcinoma patients receiving radiotherapy. *Medicine (United States)*, 102(33), E34816. <https://doi.org/10.1097/MD.00000000000034816>

Zhao, G.-Q., Xu, Y., & Wang, Q. 2005. Significance of serum vascular endothelial growth factor test before radiotherapy in patients with nasopharyngeal carcinoma. *Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine*, 3(4), 274–277. <https://doi.org/10.3736/jcim20050408>

Zhou. 2013. MEG3 noncoding RNA: a tumor suppressor. *J Mol Endocrinol*, 48(3), 45–53.

Zhou, G. Q., Ren, X. Y., Mao, Y. P., Chen, L., Sun, Y., Liu, L. Z., Li, L., Lin, A. H., Mai, H. Q., & Ma, J. 2016. Prognostic implications of dynamic serum lactate dehydrogenase assessments in nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy. *Scientific Reports*, 6(January), 1–8. <https://doi.org/10.1038/srep22326>